The Trump Administration should immediately expand availability and coverage of opioid overdose and withdrawal treatments like Adapt Pharma Ltd.’s Narcan (naloxone), while working with the pharmaceutical industry to develop new non-opioid pain treatment options, a White House commission recommends in an interim report on the opioid crisis.
The five-member commission, which is chaired by New Jersey Gov. Chris Christie (R), issued the interim report as a series...




